相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study
Bernard Uitdehaag et al.
Therapeutic Advances in Neurological Disorders (2011)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
Evidence for a two-stage disability progression in multiple sclerosis
Emmanuelle Leray et al.
BRAIN (2010)
PRISMS: the story of a pivotal clinical trial series in multiple sclerosis
Bruce A. Cohen et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Emerging effects of comorbidities on multiple sclerosis
Ruth Ann Morrie et al.
LANCET NEUROLOGY (2010)
New perspectives in the natural history of multiple sclerosis
Helen Tremlett et al.
NEUROLOGY (2010)
The Multiple Sclerosis Functional Composite A clinically meaningful measure of disability
Chris H. Polman et al.
NEUROLOGY (2010)
Real-Life Impact of Early Interferonβ Therapy in Relapsing Multiple Sclerosis
M. Trojano et al.
ANNALS OF NEUROLOGY (2009)
Magnetic Resonance Imaging as a Potential Surrogate for Relapses in Multiple Sclerosis: A Meta-analytic Approach
Maria Pia Sormani et al.
ANNALS OF NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Natural history of multiple sclerosis in a population-based cohort
M. Debouverie et al.
EUROPEAN JOURNAL OF NEUROLOGY (2008)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
Factors associated with the risk of secondary progression in multiple sclerosis
M. Koch et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Natural history of secondary-progressive multiple sclerosis
Helen Tremlett et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Validity of performance scales for disability assessment in multiple sclerosis
R. A. Marrie et al.
MULTIPLE SCLEROSIS JOURNAL (2007)
Health-related quality of life in a population-based sample of people with multiple sclerosis in Stockholm County
K. Gottberg et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
L. Kappos et al.
NEUROLOGY (2006)
Estimating long-term effects of disease-modifying drug, therapy in multiple sclerosis patients
RA Rudick et al.
MULTIPLE SCLEROSIS (2005)
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process
C Confavreux et al.
BRAIN (2003)
The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis
RA Rudick et al.
MULTIPLE SCLEROSIS (2002)
分享论文
